Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

The stock has underperformed the market over the long term.

Bristol-Myers Squibb Q3 Earnings: What Investors Should Know

Merck

Better Buy: Bristol Myers Squibb vs. Merck

AGNC Investment

Innovative Industrial Properties

This income stock trio is the perfect way to navigate volatility, should it arise.

3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Crash

Compugen

Shares of Compugen Ltd. CGEN, -2.33% gained 13.4% in premarket trading on Thursday after Bristol Myers Squibb Co. BMY, -0.12% completed a $20 million investment in the company.

Compugen's stock jumps after Bristol Myers Squibb completes $20 million investment into the company

HOLON, Israel, Nov. 11, 2021 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that Bristol Myers Squibb (NYSE: BMY) completed its $20 million investment in Compugen  in consideration for the issuance of 2,332,815 shares of Compugen purchased at $8.57333 per share, representing a 33% premium over the closing price on November 9, 2021.

Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference

Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference

Johnson & Johnson

Pfizer

Now may be a good time to buy these healthcare dividend giants.

3 Rock-Solid Healthcare Dividend Stocks Now on Sale

Amgen

Lockheed Martin

Altria

Unum

Verizon

Looking at the market today, it's clear that while some segments and companies suffer from overvaluation, this is far from a universal state. There are massively undervalued investment opportunities, where you essentially get paid to wait for the company to appreciate.

The Best 9%-25%+ Undervalued Companies Today

Enterprise Products Partners

Flowers Foods

Gaming and Leisure Properties

Huntington Bancshares

Kinder Morgan

LyondellBasell Industries

M.D.C. Holdings

Medical Properties Trust

NRG Energy

Omnicom Group

Sturm, Ruger & Company

Retail Opportunity Investments

Vale S.A.

Valero Energy

Williams

Exxon Mobil

May-August 2021, Kiplinger Today listed eight sets of stocks sorted as: best-buys for 2021, infrastructure-plays, value, growth, small-cap, high-yield, housing-bets, and cash-flow-gushers. Those eight "exceptional-dividend" articles revealed 86 equities, 76 paying dividends. Kiplinger article titles were, '21 Best Stocks to Buy'; '14 Best Infrastructure Stocks'; '16 Best Value'; '10 Dividends-Growth'; '6 Small-Cap'; '10 High-Yield 4% or More'; '12 Housing'; '10 Cash-Flow-Gushers.'

11 Exceptional November Dividend Buys

AbbVie

These companies could both diversify your portfolio and boost your dividend income.

3 Best Biotech Stocks to Buy in November

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021

Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Neoadjuvant Opdivo Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial

Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

Mastercard

Teva Pharmaceutical

Visa

Riding the Oracle of Omaha's coattails has been a moneymaking move for decades.

4 No-Brainer Buffett Stocks to Buy With $500 in November

Aurinia Pharmaceuticals

Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH21--BMS to Highlight Over 80 Abstracts at ASH 2021 Demonstrating Strong Innovative Therapeutic Platforms Improving Outcomes for Hematologic Diseases

Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases

Exelixis

Vertex Pharmaceuticals

Here are three Motley Fool contributors' top picks.

3 No-Brainer Biotech Stocks to Buy in November

The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on.

Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases

Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases

Bristol Myers Squibb's multiple sclerosis drug Zeposia could soon be approved in the EU to treat ulcerative colitis.

Bristol Myers Squibb Just Got Some Great Regulatory News

Celgene

LOS ANGELES, Nov. 1, 2021 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company ("Bristol-Myers" or "the Company") (NYSE: BMY) on behalf of former shareholders of Celgene Corporation ("Celgene") (Nasdaq: CELG) who received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) for violations of the federal securities laws. Investors who received CVRs in exchange for their shares pursuant to Bristol-Myers's $74 billion acquisition of Celgene on November 20, 2019 ("Merger") are encouraged to contact the firm before December 6, 2021.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Intel

Markets started out Monday on a positive note after a fairly impressive October. The S&P 500 saw its largest monthly gain, of about 7%, in the past year.

Monday Afternoon Analyst Upgrades and Downgrades: Bristol-Myers, Intel, Merck, Newell, Snap and More

Gilead Sciences

Takeda Pharmaceutical

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential

LOS ANGELES--(BUSINESS WIRE)---- $BMY #BMY--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Novartis

After 33 weeks and $3,400, the Dividend Harvesting Portfolio is generating $229.63 in estimated annual income and $19.14 in monthly estimated income. In week 34, I added Bristol-Myers Squibb to the portfolio and increased my position in Verizon.

Dividend Harvesting: Week 34 Update, $3,400 Allocated, $229.63 In Annual Dividends Yielding 6.7% With 50 Positions

NextEra Energy

These income stocks, with yields ranging from 1.8% to 7.4%, are the perfect place for investors to put their money to work during a downturn.

3 Can't-Miss Dividend Stocks to Buy if There's a Stock Market Crash

News for Bristol-Myers Stock (BMY)